Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review
| العنوان: | Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review |
|---|---|
| المؤلفون: | Rodrigo U Villarroel, Rama Koneru, Virtudes Soriano, Jonathan S. Zager, Roy Koruth, Olivier Dereure, Maurice Perrinjaquet, Karmele Mujika, Felix Kiecker, Eva Muñoz Couselo, Lisa A. Kottschade, Yana G. Najjar, Peter Mohr, Raluca Ionescu-Ittu, Matias Chacón, Philippe Saiag, Rebecca Burne, Jochen Utikal, Florencia Cuadros, Caroline Robert, Annie Guerin |
| المصدر: | Melanoma Management |
| بيانات النشر: | Future Medicine Ltd, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | nodal disease, medicine.medical_specialty, medicine.medical_treatment, Dermatology, Post surgery, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Chart review, melanoma, medicine, Adjuvant therapy, Stage III melanoma, In patient, 030212 general & internal medicine, Adverse effect, business.industry, Melanoma, adjuvant therapy, interferon, medicine.disease, Oncology, 030220 oncology & carcinogenesis, stage III melanoma, business, Adjuvant, Research Article, metastatic melanoma |
| الوصف: | Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011–2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe. Results: Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy. Conclusion: Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma. |
| تدمد: | 2045-0893 2045-0885 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e5aa68063aa5a868712c65807c52b74Test https://doi.org/10.2217/mmt-2019-0015Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8e5aa68063aa5a868712c65807c52b74 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20450893 20450885 |
|---|